Anika Therapeutics, Inc. (ANIK)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

17 annual periodsNewest to oldest
20252024202320222021202020192018201720162015201420132012201120102009
Revenue$112.8M$119.9M$120.8M$113.8M$147.8M$130.5M$114.6M$105.6M$113.4M$103.4M$93.0M$105.6M$75.1M$71.4M$64.8M$55.6M$40.1M
Gross profit$63.8M$76.0M$82.5M$73.2M$82.9M$69.0M$85.9M$74.3M
Research & development$25.8M$25.5M$21.8M$18.3M$27.3M$23.4M$16.7M$18.2M$18.8M$10.7M$9.0M$8.1M$7.1M$5.4M$6.2M$6.9M$8.2M
Operating income−$11.1M−$5.1M$844,000$3.7M$2.6M−$28.3M$34.2M$21.7M$45.7M$50.6M$48.1M$61.4M$32.6M$19.7M$14.0M$7.5M$5.6M
EBITDAderived−$5.7M$1.8M$7.3M$10.4M$9.1M−$22.2M$39.2M$27.7M$50.0M$54.3M$51.9M$66.2M$37.4M$24.2M$18.0M$10.9M$6.9M
Net income−$10.9M−$56.4M−$82.7M−$14.9M$4.1M−$24.0M$27.2M$18.7M$31.8M$32.5M$30.8M$38.3M$20.6M$11.8M$8.5M$4.3M$3.7M
Basic EPSper diluted share-$0.76-$3.83-$5.64-$1.02$0.29-$1.69$1.93$1.30$2.18$2.22$2.06$2.61$1.46$0.89$0.65$0.34$0.32
Diluted EPSper diluted share-$0.76-$3.83-$5.64-$1.02$0.28-$1.69$1.89$1.27$2.11$2.15$2.01$2.51$1.39$0.82$0.62$0.32$0.32

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys2$223.2K disclosed value
Sells (SEC code S)0$0.00 disclosed value
2 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
May 1, 2026Form 4HENNEMAN JOHN B IIIDirectorBuyCommon Stock5.0K$14.66$73.3K54.9K
Apr 30, 2026Form 4Griffin Stephen D.President and CEOBuyCommon Stock12.2K$12.29$149.9K36.2K